OLMA logo

OLEMA PHARMACEUTICALS INC

OLMANASDAQ
🏆 #2692 by market capEarnings Nov 9US Equity
$716.09▲ $42.68 (+5.96%)
Simulated price
🔔
Track OLMA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$752M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak
No chart data available for OLMA.

Trading Snapshot

Day Range
$704.95 – $729.21
52-Week Range
$6.65 – $36.26
Volume
$5.03B
Avg Volume
$5.64B
Shares Outstanding
87.3M
Next Earnings
Nov 3, 2026

Fundamentals Snapshot

Annual Revenue
$68M
Last Q Revenue
$17M
P/E Ratio
-4.1
P/S Ratio
0.0x
EPS (TTM)
$-1.96
Dividend Yield
0.00%
Dilution (1yr)
+55.5%

Why Investors Own OLMA

  • ✓High-growth profile — revenue up +11.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 56% gross margin and 19% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OLMA logo

OLEMA PHARMACEUTICALS INC

OLMA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$179M▲ +25.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$147M▲ +40.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
91.3M▲ +55.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$47M▼ −$91M YoY
StockOtter · stockotter.space

About OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$947.15
▲ +32.3% Upside
High Target$1,033.62
Low Target$831.61
Based on 10 analysts

Latest News & Updates

🚀
Barron’s·2h ago

OLEMA PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift OLMA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

OLEMA PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.